The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial
作者： A. Huijbers , R.A.E.M. Tollenaar , G.W. v Pelt , E.C.M. Zeestraten , S. Dutton
关键词: Medicine 、 Hazard ratio 、 Randomized controlled trial 、 Gynecology 、 Stroma 、 Colorectal cancer 、 Stage (cooking) 、 Gastroenterology 、 Microsatellite instability 、 Internal medicine 、 Survival analysis 、 Primary tumor
摘要: Background: The intra-tumor stroma percentage in colon cancer (CC) patients has previously been reported by our group as a strong independent prognostic parameter. Patients with high within the primary tumor have poor prognosis. Patients and methods: Tissue samples from most invasive part of 710 (52% Stage II, 48% III) participating VICTOR trial were analyzed for their tumor-stroma percentage. Stroma-high (>50%) stroma-low (≤50%) groups evaluated respect to survival times. Results: Overall disease-free times (OS DFS) significantly lower stroma-high P < 0.0001, hazard ratio (HR) = 1.96; DFS HR 2.15). 5-year OS was 69.0% versus 83.4% 58.6% 77.3% patients. Conclusion: This study confirms factor. parameter could be valuable low cost addition TNM status next current high-risk parameters such microsatellite instability used routine pathology reporting. When adding stroma-parameter ASCO criteria, rate ‘undertreated’ dropped 5.9% 4.3%, ‘overtreated’ increased 6.8% but correctly classified an additional 14%.
annalsofoncology.org
warwick.ac.uk
oup.com
paperity.org参考文章(22)
TNM classification of malignant tumours Published in <b>2010</b> in Chichester, West Sussex, UK ;Hoboken, NJ by Wiley-Blackwell. ,(1987) , 10.1007/978-3-642-82982-6
Karoly Szuhai, Rob A. E. M. Tollenaar, Jan M. C. Junggeburt, Pieter de Heer, Wilma E. Mesker, Hans J. Tanke, Hans Morreau, The carcinoma–stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage Analytical Cellular Pathology. ,vol. 29, pp. 387- 398 ,(2007) , 10.1155/2007/175276
Karoly Szuhai, Peter J. K. Kuppen, Rob A. E. M. Tollenaar, Gabi W. van Pelt, Jan M. C. Junggeburt, Gerrit-Jan Liefers, Wilma E. Mesker, Hans J. Tanke, Karin A. M. van Leeuwen, Paola Alberici, Hans Morreau, Noel F. Miranda, Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Analytical Cellular Pathology. ,vol. 31, pp. 169- 178 ,(2009) , 10.3233/CLO-2009-0478
W Mueller, D Treanor, P Quirke, H Grabsch, N P West, M Dattani, P McShane, G Hutchins, J Grabsch, The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients British Journal of Cancer. ,vol. 102, pp. 1519- 1523 ,(2010) , 10.1038/SJ.BJC.6605674
Seung Tae Kim, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Jin Yong Kim, Young Ho Kim, Dong Kyung Chang, Poong-Lyul Rhee, Dae Shick Kim, Haeran Yun, Yong Beom Cho, Hee Cheol Kim, Seong Hyeon Yun, Woo Yong Lee, Ho-Kyung Chun, Young Suk Park, Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemotherapy and Pharmacology. ,vol. 66, pp. 659- 667 ,(2010) , 10.1007/S00280-009-1206-3
David J Kerr, Janet A Dunn, Michael J Langman, Justine L Smith, Rachel SJ Midgley, Andrew Stanley, Joanne C Stokes, Patrick Julier, Claire Iveson, Ravi Duvvuri, Christopher C McConkey, None, Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. The New England Journal of Medicine. ,vol. 357, pp. 360- 369 ,(2007) , 10.1056/NEJMOA071841
Wouter H. de Vos tot Nederveen Cappel, Hielke J. Meulenbeld, Jan H. Kleibeuker, Fokko M. Nagengast, Fred H. Menko, Gerrit Griffioen, Annemiek Cats, Hans Morreau, Hans Gelderblom, Hans F.A. Vasen, Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer International Journal of Cancer. ,vol. 109, pp. 468- 471 ,(2004) , 10.1002/IJC.11712
Ewout F.W. Courrech Staal, Michel W.J.M. Wouters, Johanna W. van Sandick, Marijn M. Takkenberg, Vincent T.H.B.M. Smit, Jan M.C. Junggeburt, Juliette M.J. Spitzer-Naaykens, Tom Karsten, Henk H. Hartgrink, Wilma E. Mesker, Rob A.E.M. Tollenaar, The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? European Journal of Cancer. ,vol. 46, pp. 720- 728 ,(2010) , 10.1016/J.EJCA.2009.12.006
Esther M. de Kruijf, Johanna G. H. van Nes, Cornelis J. H. van de Velde, Hein Putter, Vincent T. H. B. M. Smit, Gerrit Jan Liefers, Peter J. K. Kuppen, Rob A. E. M. Tollenaar, Wilma E. Mesker, Tumor–stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients Breast Cancer Research and Treatment. ,vol. 125, pp. 687- 696 ,(2011) , 10.1007/S10549-010-0855-6
Leslie H. Sobin, Irvin D. Fleming, TNM classification of malignant tumors, fifth edition (1997) Cancer. ,vol. 80, pp. 1803- 1804 ,(1997) , 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9